SUBMIT IMAGE: The Merck logo design is seen on a sign at the Merck & Co campus in Linden, New Jersey, U.S., July 12,2018 REUTERS/Brendan McDermid
NEW YORK (Reuters) – Drugmaker Merck & Co said on Friday it plans to begin 2 large essential trials in September on the speculative oral antiviral COVID-19 drug it is establishing with independently held Ridgeback Biotherapeutics.
Speaking on a teleconference with financiers, Merck’s research study chief Roger Perlmutter said the business has actually secured manufacturing capability to make “numerous millions of dosages” of the drug before year end. The experimental drug is presently in phase 2 trials.
Reporting by Michael Erman; Modifying by Chris Reese